NDAIMPLANTATIONIMPLANT
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 22h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOLADEX (goserelin) is a GnRH agonist implant approved in 1989 for hormone-sensitive cancers and endometriosis. It works by suppressing luteinizing hormone and follicle-stimulating hormone, leading to reduced sex hormone production. The product is administered as a subcutaneous implant, typically every 28 or 84 days depending on indication.
LOE Approaching
As LOE approaches, the brand team is likely in defensive/optimization mode with potential workforce contraction; roles focus on retention and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Started Oct 2026
176 enrolled
Advanced Breast CancerEarly Breast Cancer
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
Started May 2026
132 enrolled
Aplastic Anaemia (AA)Allogeneic Haematopoietic Stem Cell TransplantationOvarian Insufficiency
Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin
Started May 2026
64 enrolled
Ovarian InsufficiencyAutologous Hematopoietic Stem Cell Transplantation
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin
Started May 2026
64 enrolled
Allogeneic Haematopoietic Stem Cell TransplantationMalignant Hematologic DiseaseOvarian Insufficiency
Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg
Started May 2023
24 enrolled
Prostate Cancer
Worked on ZOLADEX at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.